← Eichor
Study identifier: NCT07408193 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Role of Coadministration of Lidocaine and Ketamine in Opioid-Refractory Chronic Cancer-Related Pain.

Condition: Opioid-Refractory Chronic Cancer-Related Pain  ·  Sponsor: National and Kapodistrian University of Athens

PhaseEARLY_Phase 1
Planned participants24
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a randomized, double-blinded, placebo-controlled, cross-over trial examining the effect of a series of two weekly intravenous infusions of lidocaine 4 mg/kg and ketamine 0.2 mg/kg in patients with moderate to severe opioid-refractory chronic cancer-related pain. The aim of this study is to investigate whether the lidocaine - ketamine (LK) regimen provides better analgesia that an active placebo of midazolam 0.02 mg/kg, in this population.

This description comes directly from the study's public registry record.

Talk to the study team

Konstantinos Kalimeris MD, PhD, Associate Professor of Anesthesiology, Associate Professor  ·  +302105831997  ·  kkalimeris@med.uoa.gr

Erond Zeneli MD, PhD candidate  ·  +306982094129  ·  erond.zeneli@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

University General Hospital of Athens "Attikon" - National and Kapodistrian University of Athens Medical SchoolAthens, Attica, GreeceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07408193